Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | - | 20.5 | 31.9 | 13.5 | 29.7 |
| Operating profit | $m | -235 | -136 | ||||||
| Net profit | $m | - | - | - | - | -174 | -203 | -129 | -116 |
| EPS reported | $ | -4.98 | -1.06 | ||||||
| Operating cashflow per share | $ | -4.01 | -1.46 | ||||||
| Capex per share | $ | 0.07 | 0.04 | ||||||
| FCF per share | $ | -4.08 | -1.50 | ||||||
| Free cash flow | $m | -204 | -143 | ||||||
| Net debt | $m | -221 | -457 | ||||||
| Book value equity | $m | -616 | 456 | ||||||
| Book value per share | $ | -12.30 | 3.56 | ||||||
| Number of shares | m | 50.09 | 128.24 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -1.03 | 3.69 | ||||||
| P/S LTM | x | 19.87 | 124.29 | ||||||
| P/FCF LTM | x | -3.10 | -11.76 | ||||||
| EV/EBITDA LTM | x | -2.78 | -9.83 | ||||||
| EV/Sales LTM | x | 18.20 | 90.51 | ||||||
| Earnings Yield LTM | % | -32.06% | -10.77% | ||||||
| FCF Yield | % | -32.22% | -8.50% | ||||||
| Quality | |||||||||
| ROE | % | 32.98% | -153.12% | ||||||
| ROIC | % | -89.38% | -37.76% | ||||||
| Operating margin | % | -737.04% | -827.60% | ||||||
| Gross margin | % | 100.00% | 86.17% | ||||||
| FCF/Sales | % | -640.06% | -811.02% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +55.89% | -28.55% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -2.98 | -2.28 | ||||||
| Net Debt/EBITDA | x | 0.25 | 0.41 | ||||||
| EBIT/Net interest | x | -206.92 | -304.16 | ||||||
| Net debt/market cap | % | -34.96% | -27.18% | ||||||
| Net debt/Equity | x | 0.36 | -1.00 | ||||||
| Gross debt/equity | x | -0.11 | 0.14 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Generate Biomedicines, Inc. (GENB)
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free